CENTRAL TRUST Co Sells 1,319 Shares of Eli Lilly and Company (NYSE:LLY)

CENTRAL TRUST Co lessened its stake in Eli Lilly and Company (NYSE:LLY) by 2.9% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 43,761 shares of the company’s stock after selling 1,319 shares during the quarter. Eli Lilly and Company comprises about 0.9% of CENTRAL TRUST Co’s investment portfolio, making the stock its 29th largest holding. CENTRAL TRUST Co’s holdings in Eli Lilly and Company were worth $36,143,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in LLY. Mascagni Wealth Management Inc. bought a new stake in Eli Lilly and Company in the fourth quarter valued at about $43,000. FPC Investment Advisory Inc. grew its stake in Eli Lilly and Company by 358.3% in the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company’s stock valued at $45,000 after acquiring an additional 43 shares during the period. Prudent Man Investment Management Inc. acquired a new position in Eli Lilly and Company in the fourth quarter valued at about $48,000. Highline Wealth Partners LLC grew its stake in Eli Lilly and Company by 53.3% in the first quarter. Highline Wealth Partners LLC now owns 69 shares of the company’s stock valued at $57,000 after acquiring an additional 24 shares during the period. Finally, Capital A Wealth Management LLC acquired a new position in Eli Lilly and Company in the fourth quarter valued at about $63,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 2.0%

LLY stock opened at $791.61 on Wednesday. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06. The stock has a market capitalization of $750.24 billion, a P/E ratio of 64.41, a P/E/G ratio of 1.18 and a beta of 0.40. The business has a 50-day moving average of $777.90 and a 200-day moving average of $801.70. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). The company had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The business’s revenue for the quarter was up 45.2% on a year-over-year basis. During the same period last year, the company posted $2.58 earnings per share. On average, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th were issued a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.76%. The ex-dividend date of this dividend was Friday, May 16th. Eli Lilly and Company’s payout ratio is presently 48.82%.

Analyst Ratings Changes

A number of research firms have issued reports on LLY. HSBC cut Eli Lilly and Company from a “buy” rating to a “reduce” rating and decreased their target price for the company from $1,150.00 to $700.00 in a research note on Monday, April 28th. Wells Fargo & Company reissued an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Wall Street Zen raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Saturday, June 7th. Guggenheim reissued a “buy” rating on shares of Eli Lilly and Company in a research note on Friday, May 23rd. Finally, Hsbc Global Res cut Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research note on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,011.37.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.